Core Viewpoint - The company, Sihon Pharmaceutical, has received approval from the National Medical Products Administration of China for clinical trials of its dual-specific antibody-drug conjugate candidate SIM0610, aimed at treating patients with locally advanced or metastatic solid tumors [1] Group 1: Product Development - SIM0610 targets both Epidermal Growth Factor Receptor (EGFR) and c-MET, utilizing a dual-target approach to enhance anti-tumor activity and potentially overcome resistance associated with EGFR-Tyrosine Kinase Inhibitors (EGFR-TKIs) [1] - Preclinical studies have demonstrated significant anti-tumor activity of SIM0610 across various tumor models [1] Group 2: Company Profile - The company is an innovation and research-driven pharmaceutical firm, operating a national key laboratory for neuro and oncology drug development [1] - The company focuses on neuroscience, oncology, autoimmune diseases, and anti-infective fields, while strategically positioning itself in areas with significant clinical needs [1] - The company emphasizes a mission of "born for patients" and drives its initiatives through independent research and collaborative innovation, establishing strategic partnerships with various innovative enterprises and research institutions [1]
先声药业(02096)：SIM0610(EGFR/cMET双特异性抗体偶联药物)获国家药监局签发药物临床试验批准通知书